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MANAGEMENT OF PATIENTS WITH STABLE ANGINA 
 
General Outcome 
The students should be able to manage a patient with stable angina, list 
and describe specific drugs in each category of anti-anginal and anti-ischemic 
medication and uses for each 
The aim of this topic is to provide the student with an opportunity to: 
 Provide a basic overview of the pathophysiology, diagnosis, and clas-
sification of angina.  
 Evaluate guideline-based management strategies for the treatment of 
angina.  
 Discuss the role of beta-blockers, calcium channel blockers, nitrates, 
metabolic medical agent and ivabradine in the treatment of angina.  
 Develop an individualized pharmacotherapy and monitoring plan for 
the management of chronic stable angina, when given specific patient informa-
tion. 
 Develop an understanding of the principles of pharmacology of beta-
blockers, calcium channel blockers, nitrates, metabolic medical agent and se-
lective heart rate-lowering agents. 
Specific Learning Outcomes:  
Upon successful completion of this unit, the students should be able to:  
1. List and describe the anti-anginal agent classifications.  
2. Describe the mechanism of anti-anginal and anti-ischemic drugs ac-
tion and main pharmacological effects.  
3. List and describe anti-anginal and anti-ischemic drugs and give spe-
cific examples of each.  
4. Describe the adverse effects and contraindications of beta-blockers, 
calcium channel blockers, nitrates, metabolic medical agent and ivabradine.  
Specification of the theoretical question for training of “Clinico-
pharmacological characteristics of anti-anginal and anti-ischemic medical agents”  
Student must know:  
1. How do antianginal drugs affect myocardial oxygen supply and de-
mand, and how do these actions reduce chest pain?   
2. Which antianginal drugs are used to treat the following types of an-
gina, and what actions of these drugs make them suitable for a particular form 
of angina?  
а) chronic stable angina; 
б) printzmetal's variant angina;  
в) unstable angina.  
What are the mechanisms by which organic nitrate nitrodilator drugs 
1. Dilate veins and how does this relieve angina?  
 4 
2. What is drug tolerance and how does tolerance to organic nitrates af-
fect dosing?  
3. What are common side-effects to organic nitrates?  
4. Which calcium-channels blockers are approved for angina and how 
do these drugs reduce anginal pain?  
5. What preexisting conditions in patients can be made worse by admin-
istering calcium-channel blockers?  
6. Why should calcium-channel blockers not be given with beta-
blockers?   
7. Why are beta-blockers useful antianginal drugs?  
8. What are the mechanisms by which beta-blockers reduce heart rate 
and contractility (inotropy)?  
9. Define the following characteristics for beta-blockers:  
а) selective vs. non-selective beta-blockade;  
б) intrinsic sympathomimetic activity;  
в) membrane stabilizing activity.  
10. What are some common side-effects and contraindications for beta-
blockers?  
 
TESTS AND ASSIGNMENTS FOR SELF-ASSESSMENT BASIC 
LEVEL OF KNOWLEDGE: MULTIPLE CHOICE QUESTIONS 
(CHOOSE THE CORRECT ANSWER/STATEMENT) 
 
1. A 63 y.o. woman complains of sneezing heart pain irradiating to the 
left arm and neck, dyspnea. On examination: AP 140/90 mm Hg, heart rate 86 
bpm, heart boarders +1,5 cm left side, sounds are muffled, soft systolic murmur 
at apex and Botkin's area; sporadic extrasystoles. Liver isn't palpated, there are 
no edema. Blood test: WBC- 6, 7* 109/L, sedimentation rate-6 mm/hour? Gen-
eral cholesterol 6,4 mmol/l. What is the most probable diagnosis? 
A. Acute myocarditis.  
B. Rheumatism, mitral insufficiency. 
C. Climacteric myocardiodystrophia. 
D. Ischemic heart disease, angina  
     pectoris. 
E. Hypertrophic cardiomyopathy. 
 
2. A 61 y.o. man complained of sneezing and substernal pain on exer-
tion. In the last 2 weeks such pain appeared at rest, with increased frequency, 
and couldn't be suppressed by 1 tablet of nitroglycerin. What is the most likely 
diagnosis? 
A. Angina pectoris of a new onset. 
B. Myocarditis. 
C. Stable angina pectoris of the III functional class. 
D. Unstable angina pectoris. 
E. Radiculitis. 
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3. A 52 y.o. patient with previously functional Class II angina com-
plains of 5 days of intensified and prolonged retrosternal pains, decreased exer-
cise tolerance. Angina is less responsive to Nitroglycerinum. Which of the 
following diagnosis is most likely? 
A. Cardialgia due to spine problem. 
B. Myocardial dystrophy. 
C. IHD. Functional Class II angina 
D. Myocarditis. 
E. IHD. Unstable angina. 
 
. 
4.  A patient with coronary artery disease was admitted to the cardi-
ological department. For angina attack prevention a drug from the group of -
adrenoceptor blockers was administered. What drug is it? 
A. Morphine hydrochloride.  
B. Oxytocin.  
C. Metoprolol. 
D. Furosemide.  
E. Atropine sulfate.  
 
 
5. The patient has severe 3-vessel coronary artery disease and is referred 
for bypass surgery. The surgeons are concerned about his severely decreased 
LV function. Which of the following tests will NOT help predict  improvement 
in cardiac function and survival after revascularization?  
А. Dobutamine echocardiography.  
В. Electron beam computed tomography.  
С. Fluorodeoxyglucose positron emission tomography.  
D. Persantine sestamibi imaging.  
Е. Rest-rest thallium.  
 
ANSWERS 
 
1 2 3 4 5 
D D E C B 
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Introduction 
 
Ischemic heart disease is the leading cause of death and morbidity all 
over the world, with a mortality rate higher than that of all cancers combined. 
The annual mortality rate for patients with chronic angina is approximately 2%, 
but is much higher in certain subsets of patients, particularly the elderly.  
A definition of Angina: 
Angina or Angina Pectoris, is used to describe a clinical syndrome of 
pressure like chest pain precipitated by activities such as exercise or emotional 
stress which increase myocardial oxygen demand. Classical stable angina is 
predictable in onset, reproducible and relieved by rest or glyceryl trinitrate 
(GTN). Although angina can be caused by other cardiovascular condi-
tions which reduced myocardial perfusion is due to arterial narrowing resulting 
from underlying atherosclerotic coronary heart disease. A small minority of 
patients have objective evidence of myocardial ischemia in the absence of any 
obvious abnormality of the coronary arteries. 
Stable angina tends to develop over a period of several weeks without 
major deterioration allowing assessment in the outpatient setting. This is in 
contrast to the more severe changes of plaque erosion and rupture occurring as 
part of the spectrum of acute coronary syndrome. 
Angina can be graded by severity on a Canadian Cardiovascular Society 
(CCS) class scale of IV/ 
Table 1. 
Canadian Cardiovascular Society Angina Classes 
 
 
 
 
 
 
 
 
 
 
Angina is also associated with major social and economic burdens. Because 
of poor symptom control and hemodynamic, as well as other drug side effects, angina 
is commonly associated with a poor quality of life (QOL). No new class of drug has 
been available for angina treatment in more than two decades, and current medica-
tions frequently fail to provide adequate symptom control. Thus, the majority of pa-
tients are taking two or three antianginal medications. New agents that modulate 
myocardial metabolism have shown antianginal efficacy, a favorable side-effect pro-
file, and an absence of hemodynamic effects. 
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Anti-anginals are pharmaceutical agents used to treat angina pectoris, a dis-
ease of the coronary arteries. The coronary arteries supply oxygen-laden blood from 
the left ventricle to all heart muscles including those of the ventricles themselves. 
Coronary arteries maintain cardiac function and are expected to adapt to sudden de-
mands on the heart due to enhanced activity. Typically the arteries respond to this 
sudden demand by dilatation. However, it is possible that they may have developed 
atheromatous deposits that restrict the flow of blood even under normal conditions 
and more so under strenuous activity. The heart has to exert more to increase the 
blood flow through such atheroslerotic arteries. In this situation the heart is deprived 
of oxygen and feels  suffocated, a condition called ischemic. Angina is the principal 
symptom of an ischemic heart creating a sudden, severe pain that originates in the 
chest and radiates through the left shoulder down the arm.  
Myocardial ischemia is the result of imbalance between myocardial 
oxygen supply and demand. Anti ischemic drugs produce their beneficial effect 
by either improving myocardial O2 supply or decreasing demand or both. 
 
Table 2. 
Main causes of decreased myocardial oxygen supply  
or increased myocardial oxygen demands 
 
Causes of decreased myocardial 
oxygen supply 
Causes of increased 
myocardial oxygen de-
mands 
1. Progressive narrowing of epicardial coronary 
arteries by atherosclerotic (ASO) plaques. 
2. Sudden enlargement of ASO plaque. 
3. Sudden narrowing or complete occlusion of 
an epicardial coronary artery by an intracoro-
nary thrombus following rupture or erosion of 
an ASO plaque. 
4. Coronary artery spasm usually in association with 
ASO disease e.g. vasospastic (Prinzmetal) angina. 
5. Microvascular disease: disease of the small 
intramyocardial arteries secondary to abnor-
malities in vasomotor tone as in syndrome X or 
secondary to coronary microemboli from 
thrombi or ruptured atherosclerotic plaque in 
epicardial coronary artery. 
6. Other causes: coronary embolism, abnormal 
coronary rheology slow flow, compression of 
epicardial coronary artery by myocardial 
bridge, coronary ectasia. 
1. Heart rate. 
2. Arterial pressure. 
3. Myocardial inotropic 
state (contractility). 
4. LV wall stress which 
is determined by the in-
ternal LV cavity dimen-
sions and intraventricular 
pressure. LV dilatation 
will increase wall stress. 
5. An increase in LV 
muscle mass (LVH). 
6. Metabolic: free fatty 
acids, the major source of 
myocardial fuel require 
more oxygen to generate 
an equivalent amount of 
ATP when compared to 
glucose. 
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The following are the major determinants of myocardial oxygen de-
mand. Any increase of one or more of these factors will increase demand.  
Though atherosclerosis is the chief cause of coronary artery disease producing 
narrowing of coronary arteries, myocardial ischemia can occur in patients with 
normal coronary angiograms: 
1. Coronary spasm. 
2. Microvascular disease. 
3. Valvular heart disease: mitral valve prolapse, aortic valve disease, 
mitral stenosis. 
4. Pulmonary hypertension. 
5. Left ventricular hypertrophy: hypertrophic cardiomyopathy, arterial 
hypertension. 
Majority of these conditions are more common in women than in men. 
Any factor that causes an imbalance between myocardial oxygen supply 
and demand can provoke ischemia. Myocardial oxygen requirements rise with 
increases in heart rate, contractility, or left ventricular wall stress. Myocardial 
oxygen supply is determined by coronary artery flow and myocardial oxygen 
extraction. Anti-anginal medications are the mainstay of anti-ischemic man-
agement and act to correct the balance between myocardial supply and demand 
by increasing coronary blood flow, reducing myocardial oxygen requirements, 
or both.  
Diagnosis 
Base the diagnosis on the history of retrosternal chest pain with a char-
acteristic quality and duration. It may radiate to arms, neck, jaw, epigastrium or 
back. It is usually provoked by exercise or excitement and relieved by rest or 
GTN. Cold weather, a heavy meal or high altitude can precipitate angina. Vari-
ant (Prinzmetal) angina, is rare, it occurs at rest, is often more severe and pro-
longed and responds less well to GTN. Angina without chest pain may manifest 
as dyspnea on exertion. It is more likely to occur in those with diabetes or who 
have had a CABG. 
Atypical angina (vasospastic, Prinzmetal’s angina) is a rare form of 
angina and is more commonly prevalent in women. Prinzmetal first described 
it. Unlike stable angina, coronary spasm has no relation with exercise but is the 
cause of myocardial ischemia. On the contrary, the pain is sometimes relieved 
with exercise. The pain usually comes while resting or sleeping. The electro-
cardiogram may show ST elevation. The pain is relieved by glycerine trinitrate. 
Specialist investigations using provocative tests (e.g., hyperventilation, cold-
pressor testing, or ergometrine challenge) may be required to make the diagno-
sis. Ventricular arrhythmia and heart block may occur. Calcium channel block-
ers (CCBs) may prevent coronary spasm, but beta-blockers may worsen the 
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symptoms. However, patients may remain symptom-free for months or years. 
Like unstable angina, there is a subsequent risk of heart attack. 
Investigations may be helpful in elucidating the cause of the angina and 
the severity of the coronary artery occlusion but they cannot refute a diagnosis 
based on a clear history. 
Assessment 
History and examination: 
1. Ask about smoking and exercise. 
2. Ask about other risk factors for CVD (family history, diabetes, hyper-
tension, hyperchoesterolaemia and ethnic origin if relevant). 
3. Check BP. Treat if 2 readings over 2 monthly intervals show it is = 
140/90. Aim for <140/85. Blood pressure targets are lower (130/80) if the pa-
tient has established CVD, chronic renal disease or diabetes.  
4. Check the heart for valvular disease. Any aortic systolic murmur 
needs assessment for aortic stenosis unless the patient’s general condition is too 
poor to consider even a valvotomy. 
5. Check for evidence of arrhythmia, heart failure, and peripheral vascu-
lar disease. 
6. Check weight, height and BMI. 
7. Waist circumference may be used to assess central obesity. 
Baseline investigations: 
 Hb; CBC 
 TFT, LFTs; CK; U&Es; 
 fasting blood sugar; 
 fasting lipid profile; 
Investigations for confirming diagnosis  
 Resting electrocardiogram (ECG) 
 ECG stress testing 
 Ambulatory ECG monitoring (Holter monitoring) 
 Echocardiography at rest 
 Stress echocardiography 
 Myocardial perfusion scintigraphy 
 Radionuclide angiography during exercise 
 Coronary angiography 
 Intravascular ultrasound 
Clinical history and examination are very important. The speed with which 
the investigations are undertaken depends on the urgency, taking into account the age 
of the patient, the presence of other risk factors, the severity of chest pain, the likeli-
hood of the diagnosis, and the findings on clinical examination. Chest x-ray helps to 
exclude congestive heart failure, valvular lesions, pericardial disease, or aortic dissec-
tion/aneurysm. However, the use of routine chest x-ray is not well established. 
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Blood tests should include tests for anemia, thyroid function (TFT), 
urea, electrolytes, lipid profile, glucose and cardiac enzymes, troponin, erythro-
cyte sedimentation rate (ESR) and high-sensitivity C-reactive protein (hsCRP). 
Resting electrocardiogram (ECG) is indicated in all cases as an initial test, 
although a normal ECG does not exclude CAD. Evidence of a prior Q-wave on 
ECG and evidence of left ventricular hypertrophy also increases the probability 
of angina. If the resting ECG is normal, depending on the likelihood of the 
diagnosis, treadmill stress testing is arranged.  
The treadmill test is most valuable when the pretest probability is inter-
mediate, for example, when a 50-year-old man has atypical angina and the 
probability of CAD is about 50%. When the probability of CAD is high, a posi-
tive test result only confirms the high probability of disease, and a negative test 
result may not decrease the probability of CAD enough to make a clinical dif-
ference. When the probability of CAD is very low, a negative test result only 
confirms the low probability of disease; a positive test may not increase the 
probability of disease enough to make a clinical difference. If there is high 
suspicion of CAD, then exercise testing could be combined with thallium test-
ing (myocardial perfusion imaging [MPI]) or angiography. Exercise ECG (also 
known as a stress test or Exercise Tolerance Test (ETT); The exercise ECG as a 
key investigation. This is in order to single out those patients who might benefit 
from angioplasty or CABG.  
Reasons for not performing an exercise ECG: 
 the patient is physically incapable of performing the test; 
 the patient has some other illness or condition which would make 
them unsuitable for coronary artery surgery or Percutaneous coronary 
intervention; 
 the diagnosis is in doubt (an exercise ECG has low specificity for mak-
ing the diagnosis of angina); 
 symptoms are uncontrolled by medical treatment (such patients should 
be referred for angiography). 
ECG shows Left Bundle Branch Block which makes Exercise ECG in-
appropriate  
Myocardial Perfusion scan; may be requested by a Cardiologist for 
those patients unable to undergo ETT. Myocardial perfusion scintigraphy has 
been recommended as the initial diagnostic tool for people with suspected 
Coronary Artery Disease (CAD) for whom ETT poses particular problems.  
Echocardiography is usually not indicated in most patients, unless valvular 
disease or hypertrophic cardiomyopathy is suspected. Coronary angiography is 
very important in the diagnosis where myocardial ischemia is suspected and 
noninvasive testing is contraindicated. 
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The recommendations are for cardiac stress imaging as the initial 
test in the following situations: 
1. Exercise ECG for the diagnosis of obstructive CAD. 
2. Exercise myocardial perfusion imaging or exercise echocardiography 
when the patient has intermediate pretest probability of CAD or has ei-
ther Wolff-Parkinson-White syndrome or more than 1mm of rest ST depres-
sion. 
3. Exercise MPI or exercise echocardiography if there is a past history 
of revascularization. 
4. If a patient is not able to exercise, then adenosine or dipyridamol MPI 
or dobutamine echocardiography is indicated if patient has either an intermedi-
ate pretest probability of CAD or a past history of revascularization. 
When the probability of severe angina is low, noninvasive tests are 
most appropriate. However, when the pretest probability is high, direct 
referral for coronary angiography is a suitable choice. Stress imaging tests 
such as the radionuclide MPI test or two dimensional echocardiography at 
rest and during stress are valuable for the purpose of risk stratification 
and planning the best route of management. A normal thallium scan is 
highly indicative of a benign prognosis even in patients with known CHD. 
Coronary angiography is usually not indicated unless other measures 
show high risk. Stress echocardiography is also able to provide additional 
prognostic information. 
Coronary angiography is most useful in the following situations: 
1. If a patient suspected of CAD survived sudden cardiac death 
2. Uncertain diagnosis after noninvasive tests  
3. If the patient is unable to undergo noninvasive tests. 
4. Patients in whom coronary artery spasm is suspected and provocative 
tests may be necessary. 
5. Patients with a pretest probability of left main stem or three vessel 
disease. 
6. Occupational requirement for a firm diagnosis. 
7. To exclude anatomical anomalies in young patients as the cause of 
angina.  
8. Those with atypical symptoms but a strongly positive exercise ECG. 
Differential diagnosis of the symptoms 
If all the above mentioned cardinal features are present, or even only the 
first two are quite typical, then the diagnosis of chronic stable angina is virtu-
ally assured. Often, however, the picture is not so clear-cut and other diagnoses 
must be considered (table 4). 
 
 
 12 
Table 3 
Definitions of stable angina and acute coronary syndromes 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4 
Alternative diagnosis to angina for patients with chest pain  
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Tests for risk assessment and prognosis in a patient with chronic stable angina 
The following factors are associated with worse prognosis: 
 One of the strongest and most consistent prognostic markers is the 
maximum exercise capacity. Poor exercise tolerance, either due to myocardial 
ischemia or left ventricular dysfunction, is a bad marker. 
 Another important prognostic marker is related to exercise induced 
ischemia. ST-segment depression and elevation (in leads without pathological 
Q waves and not in aVR) best summarize the prognostic information related to 
ischemia. 
 Left ventricular dysfunction or ejection fraction is less than 40%. 
 Exercise stress test shows ST segment depression >2mm, poor exer-
cise tolerance, or a fall of blood pressure. 
 Myocardial perfusion test shows thallium uptake in the lungs. 
 Angiography shows left main-stem involvement or multivessel dis-
ease, especially in the presence of left ventricular systolic dysfunction. 
 Chest x-ray shows cardiomegaly, left ventricular aneurysm, or pulmo-
nary venous congestion. 
 A family history of myocardial infarction (MI) and diabetes is an in-
dependent predictor of death for coronary heart disease (CHD). 
 Increasing age. 
 Male gender, but after menopause females have a similar risk. 
 
GENERAL MEASURES & TREATMENT OF STABLE ANGINA 
Advise the patient: 
(a) not to smoke. After 9 years, the risks for an exsmoker fall to those of 
a nonsmoker; 
(b) to lose weight, if obese; 
(c) to take adequate exercise. This means 30 minutes moderately intense 
exercise, e.g. brisk walking, 5 times a week. The 30 minutes may be divided 
into separate parts, but each bout of exercise should last at least 10 minutes; 
(d) to eat a low saturated fat, Mediterranean diet, with oily fish 
twice a week; 
* Driving. The patient should not drive while symptoms are uncon-
trolled. Group 2 licence holders (large lorries and buses) and holders of a pi-
lot’s licence must inform the appropriate authority and stop driving/flying 
meanwhile. 
* Vaccination: recommend influenza annually and pneumococcal vacci-
nation once. 
* Quality of life. Ask what effect the angina is having on the patient. 
Look especially for depression, erectile dysfunction and unnecessary invalid-
ism. 
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1. Short term control of angina symptoms 
Advise the patient about the symptoms of a myocardial infarction or un-
stable angina and the importance of calling an ambulance if chest pain persists 
for >15 minutes despite the use of GTN. 
Glyceryl trinitrate (GTN): 
(a) sublingual tablets: 500 mg.per tablet; or 
(b) sublingual spray: 400 mg per puff; 
* When chest pain occurs, rest and take one or two tablets/sprays under 
the tongue if one or two tablets/sprays are not effective repeat the dose after 5 
minutes, if necessary repeat after 10 minutes. 
* GTN may also be administered a few minutes prior to encountering an 
anginaprecipitating stimulus (planned exertion). 
* GTN may cause severe headaches which often become less severe with 
continued use. 
GTN tablets can be discarded once pain is relieved thereby reducing the 
dose taken and occurrence of headache. 
* If tablets are used advise about storage and expiry; keep in original 
darkened bottle and dispose of 8 weeks after opening. 
If sublingual GTN is not tolerated/effective: 
(c) Buccal tablets: 2mg, which may be more effective than sublingual 
preparations. 
If angina occurs while the buccal tablet is in place, the dosage strength 
used should be increased to 3mg. The 5mg dosage strength should be reserved 
for patients with severe angina pectoris refractory to treatment with the lower 
dosage strengths. 
* For patients suffering only occasional angina pectoris – the tablets 
may be administered on a p.r.n. basis to relieve the acute attack. 
* The tablet may also be administered a few minutes prior to encounter-
ing an anginaprecipitating stimulus. 
Long term control of angina symptoms 
Each of these drug classes decreases cardiac workload and may increase 
coronary blood flow or improve its distribution and thus modify the imbalance 
between myocardial supply and demand. Although monotherapy is effective in 
some, the majority of patients require two or more antianginal agents to control 
their symptoms. The choice of first-line treatment remains controversial be-
cause no single class of drug has demonstrated unequivocal superiority. Long-
acting nitrates, β-adrenergic blocking agents, and calcium channel blockers, 
either alone or in combination, have been proven effective in reducing the fre-
quency of angina. 
The medical treatment of angina has changed little in the past few years. 
Nitrates were first described for treatment of the condition by Brunton in 1867. 
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Beta-blockers were introduced for treatment in the 1960s, following the devel-
opment of specific beta-antagonists by James Black. Pronethalol was the 
first beta-blocker, but because of its side effects it was replaced by pro-
pranolol. There has since been a proliferation of beta-blockers with different 
pharmacological properties such as duration of action, lipid solubility, and 
cardiac specificity. Beta-blockers have been shown in large trials to have clini-
cal efficacy not only in the treatment of angina but also in hypertension, post-
myocardial infarction, and heart failure.  
The calcium antagonists were introduced in the 1970s for angina and 
are presumed to have their major impact by increasing coronary flow as a con-
sequence of dilatation of the coronary vessels. 
Current treatment of chronic angina 
Current wisdom suggests that antianginal agents are first-line therapy, 
reserving revascularization procedures for patients who do not show an ade-
quate response to pharmacologic therapy. Various drugs have been used to 
relieve acute attacks and others have been used prophylactically to prevent 
anginal episodes. 
The several classes of drugs commonly used for chronic angina, and include: 
• short- and long-acting nitrates; 
• β - adrenergic blocking agents; 
• calcium channel blockers;  
• metabolic anti-anginal drugs; 
• selective heart rate-lowering agents  
Organic nitrates. Nitrates do not improve long-term morbidity and 
mortality and therefore are mainly used only for symptom control. An impor-
tant point to remember about using nitrate therapy is the development of nitrate 
tolerance. The onset of tolerance can be as early as 24 hours in some patients. 
To prevent nitrate tolerance, maintaining a nitrate-free interval of 6-12 hours 
daily is crucial. During the nitrate-free period, patient may develop angina (as 
there are no nitrates in the body to protect them). Therefore, nitrates should 
never be used alone as the only anti-anginal therapy for patients. They should 
always be used with one or more of the other antianginal therapies, such as b-
blockers or calcium channel blockers. 
Short- and  
Nitrates have been used to treat angina pectoris for over a century, and the 
efficacy of sublingual nitroglycerin in the relief of effort-mediated angina pec-
toris is unequivocal. Controversy exists, however, as to the mechanism of ac-
tion of nitrates. There is also disagreement as to the utility of other forms of 
nitrate preparations in the relief of angina pectoris. 
Two long-acting organic nitrates are currently used: 
1. Isosorbide dinitrate (ISDN). 
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2. Isosorbide mononitrate (ISMN). 
These drugs are available in a variety of formulations with different routes 
of administration (Table 5).They are prodrugs and undergo biotransformation 
in which nitrite ion (NO2¯) is released and metabolized to nitric oxide (NO). 
The nitrates are rapidly absorbed from the gastrointestinal tract, skin, and 
mucous membranes. Isosorbide dinitrate and nitroglycerin undergo extensive 
first-pass hepatic metabolism when given orally. Nitroglycerin has a plasma 
half-life of approximately one to four minutes. It undergoes hepatic and in-
travascular metabolism, yielding biologically active dinitrate metabolites that 
have a half-life of approximately 40 minutes. 
Isosorbide dinitrate, although it has hemodynamic and antianginal effects,is 
rapidly metabolized, with a plasma half-life of approximately 40 minutes. Its 
major metabolites, isosorbide-2-mononitrate and isosorbide-5-mononitrate,are 
both biologically active, with half-lives of approximately two and four hours, 
respectively. Isosorbide mononitrate (isosorbide-5-mononitrate), does not un-
dergo first-pass hepatic metabolism and is completely bioavailable. 
Mechanism of action: 
Molecular mechanism of action. Nitrates act through endothelial-
independent pathway to relax all types of vascular smooth muscle cells to vary-
ing degrees. 
The organic nitrates are prodrugs and must be biodegraded to have 
therapeutic effects. This biotransformation involves denitration of the nitrate, 
with the subsequent liberation of nitric oxide. 
Nitric oxide stimulates guanylyl cyclase, which leads to the conversion 
of guanosine triphosphate to cyclic guanosine monophosphate, which in turn 
causes vasodilation through decrease in intracellular calcium level. The exact 
mechanism by which the organic nitrates undergo denitration and thus liberate 
nitric oxide remains controversial. In addition to exerting vasodilating effects, it 
reduces platelet adhesion and aggregation. Nitric oxide is also involved in the 
control of endothelial function and vascular growth as well as my ocardial 
contractility. Therefore, the nitrates possess a unique combination of vascular 
effects that can favorably affect the mismatch between myocardial oxygen 
supply and demand in patients with coronary artery disease. 
A. Increase coronary blood supply. 
1. Dilatation of large coronary arteries and arterioles (>100 mu in di-
ameter), this will lead to increased perfusion of ischemic zones. Nitrates dilate 
both normal and abnormal coronary arteries. 
2. Relief of coronary artery spasm. 
3. Dilatation of coronary collaterals and enhancement of collateral flow. 
4. Redistribution of transmural coronary blood flow from subepicardial 
to subendocardial ischemic regions. 
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B. Decrease myocardial oxygen consumption. 
This is the chief mechanism for relief of ischemia by nitrates. 
Systemic venous relaxation in the extremities and splanchnic circulation 
results in sequestration of the circulating blood volume away from the heart and 
lungs and fall in venous return and cardiac filling. 
1. Venous dilatation with decreased LV filling pressure and decreased 
preload can reduce ventricular volume and decrease LV wall stress – a major 
determinant of myocardial oxygen consumption. The fall in preload is more 
pronounced with sitting or standing. Vasodilatation develops at low nitrate 
concentration and is near maximal at moderate dosage. 
2. Arterial dilatation: nitrates dilate large and small arteries with 
fall in vascular impedance and decrease in arterial pressure, resulting in 
reduction in afterload. 
Other actions. 
1. Pulmonary arterial bed relaxation: beneficial in subjects with secon-
dary pulmonary hypertension. 
2. Antiplatelet action: decreased platelet activation resulting in inhibi-
tion of platelet aggregation and less thrombosis. Stimulation of platelet 
guanylate cyclase by nitrates prevents fibrinogen binding to platelet GP IIb/IIIa 
receptors. 
Contraindications. 
1. Patients who have taken sildenafil (Viagra) within 24 hours because 
of the risk of severe hypotension. 
2. Patients with hypertophic cardiomyopathy even those without a rest-
ing gradient across left ventricular outflow tract. 
3. Patients with suspected right ventricular infarction because of 
risk of hypotension. 
4. Use cautiously in patients with severe aortic stenosis or with 
volume depletion. 
Nitrate preparations 
Nitroglycerin (NTG) 
 Available in many formulations, parenteral, sublingual, buccal, oint-
ment and patch. 
 It has a very short half-life of several minutes; cessation of an intrave-
nous NTG infusion or removal of transdermal patch results in a rapid fall of 
NTG plasma level within 20 to 40 minutes. 
 Veins take up NTG more avidly than arteries. 
Dosages. Sublingual NTG: 0.3-0.6 mg, onset of action is 2-5 minutes 
and its duration is 20-30 minute. The usual tablet dose is 0.3 mg to 0.4 mg 
repeated every five minutes for a total of three doses. NTG tablets are both heat 
and light sensitive. They should be stored in a tightly capped dark bottle in the 
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 refrigerator. Prescription should be renewed every three to six months. 
 NTG patch: 0.4-0.8 mg/h, the patch should be applied for only 12-14 
hours each day. 
 Oral NTG: has no reliable data supporting its effectiveness. 
 Intravenous NTG: initiated at a rate of 10 mcg per minute through con-
tinuous infusion and increased by 10 mcg/min every 3-5 minutes until symptom 
relief or blood pressure response is noted. 
 If no response is seen increments of 20 mcg/min can be used. If symp-
toms and signs of ischemia are not relieved, the dose should be increased until a 
blood pressure response is observed. 
 Caution should be used when systolic blood pressure falls below 110 
mmHg in previously normotensive patients or to a greater than 25% below the 
starting mean arterial blood pressure if hypertension was present. 
 Maximal dose of 400 mcg/min should not be exceeded. 
Table 5. 
Long acting oral organic nitrate 
 
Isosorbide dinitrate (ISDN) Isosorbide mononitrate  (ISMIN) 
 The most widely used long acting nitrate. 
 Available as short-acting and sus-
tained-release formulation. 
 Onset of action is within 15 to 30 min-
utes and the duration of action is three to 
six hours. There is low bioavailability 
from hepatic metabolism. 
 Dosage: 10 to 40 mg three times 
daily. There is no added benefit with 
60 and 120 mg doses. 
 Tolerance has limited the usefullness of 
ISDN as a chronic antianginal agent. 
 Development of tolerance occurs 
despite higher plasma concentrations of 
ISDN during maintenance therapy. 
 To prevent the development of 
tolerance, it is recommended to give 
ISDN at 8 AM, 1 PM and 6 PM. This 
regimen can offer antianginal protec-
tion for at least six hours. 
 Begin with a dose of 10 mg three 
times daily and advance to 40 mg 
three times daily as needed. 
 Onset of action is within 30 minutes, and 
the duration of action is six to eight hours. 
 It is completely bioavailable. 
 The usual starting dose is 20 mg twice 
daily to be increased to 40 mg twice 
daily if necessary. 
 Seven hours interval between doses 
followed by 17 hours nitrate-free interval. 
 Extended (sustained) release preparation 
is given once daily and lasts 12 hours. 
 A minimum of 60 mg per day is rec-
ommended, higher doses such as 120 or 
240 mg daily may be necessary for sus-
tained antianginal efficacy without toler-
ance. Sustained release preparation action 
lasts for 12 hours, nocturnal or rebound 
angina may develop. 
 ISMN preparations (tablet size): 
 Regular: 20, 40 mg 
 Sustained release (SR): 25, 50 mg 
 Extended release preparations are prefer-
able. Starting dose is 30 mg once daily can 
be titrated to 120 mg once daily as needed. 
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Suggestions for nitrate dosing 
 Start nitrate therapy with small doses and build up to maximally toler-
ated amount. 
 Some individuals are extremely sensitive to nitrates; others experience 
little or no side effects. 
 Headache and dizziness are the limiting symptoms with nitrate ad-
ministration. They usually decrease or disappear over time. 
 Many patients are under dosed e.g. 10 mg ISDN, 30 or 40 mg ISMN-SR or 
0.2 to 0.4 mg/h of the NTG patch are less likely to be clinically effective doses. 
 In congestive heart failure, the dosage of nitrates to achieve a signifi-
cant hemodynamic effect is considerably higher than in patients with normal 
LV function. Patients with congestive heart failure tolerate large doses. 
 In patients with primarily exertional angina, nitrates are given during 
the day when the patient is more active. 
 In patients with nocturnal angina or congestive heart failure, therapy 
at night is advised. 
 When given in adequate dosage, there is no difference in efficacy be-
tween ISDN, ISMN and transdermal NTG. 
 
Table 6. 
Common nitrate preparation 
 
Prepa-
ration 
Route of 
administration 
Onset of 
action, 
minutes 
Duration  
of action Dose 
Sublingual tablet 2-5 15-30 min 0.15-0.9 mg 
Sublingual spray 2-5 15-30 min 0.4 mg 
Ointment 2-5 Up to 7 hours 
2 percent, 15x15 
cm  (7.5 to 40mg) 
Transdermal 30 8-14 hours 0.2-0.8 mg/hour 
Oral sustained 
release 30 4-8 hours 2.5-13 mg 
Nitro-
glycerin 
Intravenous 2-5 Drug infu-sion 5-200 mg/min 
Sublingual 2-5 Up to 60 min 2.5-15 mg 
Oral 30 Up to 8 hours 5-80 mg BID or TID
Spray 2-5 2-3 min 1.25 mg/day 
Chewable 2-5 2-2.5 hours 5 mg 
Isosor-
bide 
dini-
trate 
Oral slow release 30 Up to 8 hours 40 mg OD or BID 
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Isosor-
bide 
mononi-
trate 
Oral 30 6-8 hours 20-40 mg BID 60-240 mg/day 
Isosor-
bide 
mononi-
trate, 
ex-
tended 
release 
Oral 30-60 12 hours 30-120 mg once daily 
Pentae-
rythroid 
tetrani-
trate 
Sublingual 2-5 Not known 10 mg as needed 
Sublingual 2-5 Not known 5-10 mg as needed 
Eyrthri-
tol 
tetrani-
trate Oral 30 Not known  
 
BETA-ADRENERGIC BLOCKERS (BABS) 
 
In patients with IHD or history of myocardial infarction, b-
blockers reduce recurrent cardiovascular events. In using b-blockers in 
patients with IHD, no b-blockers with intrinsic sympathomimetic activi-
ties should be used because their partial agonistic effect may increase 
instead of decrease myocardial workload. 
Between beta-blockers and calcium channel blockers, b-blockers are 
generally considered the anti-ischemic agent of choice except in the case of 
Prinzmetal angina where beta-blockers are relatively contraindicated because of 
possible coronary vasospastic effects. Dosing beta-blockers in IHD is different 
from dosing in hypertension where achieving a target blood pressure is the 
goal. Our therapeutic target is a resting heart rate of 50 to 60 beats per minute 
(provided the patients’ blood pressure remains stable).  
Beta-blockers. 
• The only group of antiischemic drugs with documented efficacy in 
preventing reoccurrence of coronary events, myocardial infarction (MI) and 
sudden death following acute MI. 
• BABs act as competitive inhibitors of catecholamines at beta-
adrenergic receptors (BARs). 
• BARs are divided into B1 (those in the myocardium) and B2 (present 
in smooth muscle cells, bronchi and other tissues). Epinephrine and nor-
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epinephrine are equipotent at B1 receptors, whereas epinephrine is 10 to 50 fold 
more potent than nor-epinephrine at B2 receptors. 
• Cyclic adenosine mono phosphate (cAMP) is the major second mes-
senger of BAR stimulation leading to events that increase influx of calcium into 
the cell and activate glycogen phosphorylases. 
• The metabolic effects of cyclic AMP including calcium overloading, 
high energy phosphate depletion, oxygen wastage by increased free fatty acid 
metabolism and increased arrhythmogenicity appear to play a role in cate-
cholamine induced ischemic cell injury.  
Development of the beta-adrenoceptor antagonists. The discovery 
and development of the b-adrenoceptor antagonists represents one of the most 
significant advances in the history of cardiovascular pharmacology and thera-
peutics Sir James Black is credited with leading the team that discovered the 
first clinically useful b-adrenoceptor antagonist, propranolol, which was devel-
oped specifically for the treatment of angina.  
Black proposed that pharmacologic blockade of cardiac b-adrenoceptors 
would reduce heart rate and myocardial oxygen demand and thereby prevent 
angina of effort associated with activation of the sympathetic nervous system 
(eg, exercise,emotional stress, anxiety). This was a novel concept at that time 
(late 1950s, early 1960s) since the only effective antianginal drugs were the 
organic nitrates, such as nitroglycerin, whose therapeutic effects were attributed 
to vasodilation and increased coronary blood flow. Although there were no 
known b-adrenoceptor antagonists in existence, isoproterenol, a relatively pure 
b-adrenoceptor agonist that mimics the actions of norepinephrine and epineph-
rine on the heart, was available. 
Black reasoned that isoproterenol must possess the requisite structural 
characteristics necessary for interacting with cardiac b-adrenoceptors. Using 
isoproterenol as a starting point, he had his chemists synthesize numerous 
molecules that were chemical derivatives of the b-adrenoceptor agonist, ulti-
mately leading to the discovery of propranolol. Black was awarded the Nobel 
Prize in 1988, in part, for his role in the discovery of propranolol and the ap-
proach that he used. 
Classification of BABS. More than 30 BABs are present worldwide. 
They are classified according to the following characteristics: 
1. Beta-adrenergic specificity- selectivity. 
2. Lipid solubility- lipophility. 
3. Intrinsic sympathomimetic activity (ISA). 
4. Vasodilator properties. 
Three distinct subtypes of b-adrenoceptors, termed b1, b2, and b3, have 
been identified. With regard to the actions of epinephrine and norepinephrine in 
the cardiovascular system, increases in heart rate and force of contraction are 
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mediated primarily via activation of b1-adrenoceptors in the heart, while vaso-
dilation is mediated primarily by activation of b2-adrenoceptors in vascular 
smooth muscle. 
Selectivity for b1-adrenoceptors is referred to as ‘‘cardioselectivity’’, and 
represents an important pharmacologic property that can be used to distinguish 
among b-adrenoceptor antagonists. Other pharmacologic properties that differ-
entiate the b-adrenoceptor antagonists include intrinsic sympathomimetic activ-
ity (ie, partial agonist), membrane-stabilizing activity (ie, local anesthetic like 
effects), and concomitant a-adrenoceptor blockade, though these properties are 
not required for efficacy in the treatment of angina.  Important pharmacokinetic 
differences include variations in lipid solubility, bioavailability, half-life and 
elimination (renal vs. hepatic). 
1. Beta-adrenergic specificity- selectivity 
 Some BABs are more specific for B1 ARs, they are called cardio-
selective BABs, examples are atenolol, metoprolol and bisoprolol. Bisoprolol is 
the most cardioselective BAB (table 6). Other BABs are non selective and 
block both B1 and B2 ARs. Examples are propranolol and nadolol. 
 In low doses, B1- selective blockers may not block the B2- receptors 
that mediate dilatation of arterioles and bronchi and have a number of meta-
bolic effects. Cardioselective BABs are relatively safer in the management of 
patients with COPD, diabetes and peripheral vascular disease (PVD). However, 
when given in large doses they block both B1 and B2 receptors. 
Advantage of B1- Selectivity 
 Glucose metabolism: no dose adaptation of oral hypoglycemics. 
 Lower risk of masking hypoglycemia. 
 Pulmonary function: safe use with COPD. 
 Peripheral vascular resistance: lower risk of cold extremities and erec-
tile dysfunction. 
2. Lipophility 
 Lipid soluble BABs are metabolized by the liver, they have a short du-
ration of action and tend to have central nervous system side effects. Examples 
are propranolol, metoprolol, carvedilol and timolol. 
 Water soluble (lipid insoluble) BABs are excreted through the kid-
neys, they have a longer duration of action and less central nervous system side 
effects. Examples are atenolol, bisoprolol, and nadolol. 
3. Intrinsic sympathomimetic activity (ISA) 
BABs with this property slightly activate the BARs in addition to pre-
venting the access of natural or synthetic catecholamines to the receptor. Drugs 
with partial agonist activity cause less slowing of the heart rate at rest and cause 
less depression of atrioventricular conduction. Examples are pindolol. 
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4. Vasodilator properties 
 Some BABs block both alpha and beta ARs and have direct vasodila-
tor activity. Examples are labetalol and carvedilol. Bucindolol is a non-
selective BAB with a direct vasodilator activity.  
Table 7. 
Adrenergic receptor blocking affinities  
 
Generation/Class Compound B1,/ B2 Selectivity 
First/ Nonselective Propranolol 2.1 
Second/ Selective B1 Metoprolol 
Bisoprolol 
74 
119 
Third/ B-blocker-
vasodilator 
Carvedilol 
Bucindolol 
Nebivolol 
7,3 
1,4 
293 
 
Pharmacokinetic properties. Most b-adrenoceptor antagonists are well 
absorbed following oral administration, but many undergo firstpass hepatic 
metabolism; thus, the oral bioavailability of b-adrenoceptor antagonists is lim-
ited to varying degrees. The oral bioavailability of propranolol is approximately 
25%-30% on average, but it is dose-related and subject to considerable varia-
tion among individuals. 
Oral bioavailability of metoprolol (~50%) is also limited by first-pass 
metabolism. The elimination of propranolol and metoprolol may be decreased 
in the presence of liver disease or advanced age. Nadolol and atenolol are hy-
drophilic and are incompletely absorbed following oral administration. 
Bioavailability of nadolol (~35) and atenolol (~40%) is little influenced by 
hepatic metabolism and both drugs are excreted essentially unchanged in the 
urine. These drugs show less interpatient variation in plasma levels than pro-
pranolol and metoprolol, but their elimination may be reduced by renal disease. 
Half-lives range from about 4 hours for propranolol and metoprolol, to about 8 
hours for atenolol, and up to 24 hours for nadolol. 
Extended release oral dosage forms are available for propranolol and 
metoprolol. Propranolol, metoprolol, and atenolol may also be administered by 
intravenous injection. The pharmacodynamic effects of the b-adrenoceptor 
antagonists often extend well beyond the time predicted by their half-lives. 
Mechanism of anti-ischemic action of BABS 
A. Decrease in myocardial oxygen requirements 
1. Slowing of heart rate. 
2. Lowering of blood pressure. 
3. Decrease in myocardial contractility. 
4. Decrease in fatty acid utilization. 
 
 24 
B. Increase in myocardial oxygen supply 
1. Increase in diastolic perfusion and augmentation of coronary blood 
flow secondary to bradycardia. 
2. Augmentation of collateral blood flow and redistribution of blood 
flow to ischemic areas. 
C. Other actions 
1. Stabilization of atherosclerotic plaque and preventing plaque rupture 
through reduction in vessel wall stress. 
2. Decrease in microvascular damage. 
3. Stabilization of cell and lysosomal membranes. 
4. Inhibition of platelet aggregation. 
Hemodynamic effects: myocardial oxygen demand. Beta-adrenoceptor 
antagonists competitively inhibit the binding of endogenous catecholamines to b1-
adrenoceptors in the heart and most evidence strongly suggests that their anti-ischemic 
effects are due to cardiac depression. Myocardial oxygen demand is determined in large 
part by heart rate and cardiac contractility. Increased heart rate and contractility result in 
increased myocardial oxygen consumption and, conversely, reductions in heart rate and 
contractility lead to a decrease in oxygen consumption. By inhibiting the actions of norepi-
nephrine and epinephrine on the heart,the b-adrenoceptor antagonists reduce myocardial 
oxygen demand via a reduction in both heart rate and cardiac contractility and thereby 
attenuate the myocardial response to sympathetic nervous system stimulation that occurs, 
for example, with increased stress or exercise. 
Though most b-adrenoceptor antagonists lower resting heart rate to some ex-
tent, the effect on exercise-induced tachycardia is much more pronounced. Thus, for a 
given degree of physical activity, myocardial oxygen consumption is diminished. It is 
important to note that the b-adrenoceptor antagonists do not change the point of im-
balance between myocardial oxygen supply and consumption at which angina occurs; 
rather, they reduce the likelihood that this point is reached. 
By mechanisms that remain poorly understood, b-adrenoceptor antagonists 
also decrease peripheral vascular resistance, which leads to a reduction in arterial 
blood pressure and afterload. Reduced afterload results in decreased left ventricular 
wall tension, which is another major determinant of myocardial oxygen demand.  
This beneficial effect of the b-adrenoceptor antagonists may be partially off-
set, however, by an increase in left ventricular end-diastolic volume that occurs due to 
increased cardiac filling during diastole, but the net effect is to lessen oxygen demand. 
Hemodynamic effects: myocardial oxygen supply. The heart is almost exclusively 
dependent on aerobic metabolism and an adequate supply of oxygen is critical to sustained 
cardiac activity. Myocardial oxygen supply is a function of both oxygen delivery and oxygen 
extraction from the blood. Since oxygen extraction from coronary blood is near maximal at rest, 
there is little reserve to meet increased demand due to increased cardiac activity. Thus, the most 
important determinant of myocardial oxygen supply is total coronary blood flow. 
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Since b-adrenoceptor antagonists are not coronary vasodilators, they have little 
propensity to increase coronary blood flow and myocardial oxygen supply. If anything, b-
adrenoceptor antagonists may increase coronary vascular resistance by inhibiting the b2-
adrenoceptor mediated vasodilator effects of endogenous catecholamines and leaving a-
adrenoceptor-mediated vasoconstriction unopposed. Thus, the anti-ischemic effects of the 
b-adrenoceptor antagonists are largely due to their ability to reduce myocardial workload 
and decrease oxygen consumption, rather than to improve myocardial oxygen supply. 
Table 8. 
Indications of BABS 
 
A. Cardiovascular B. Non-cardiovascular 
1. Chronic stable angina. 
2. Acute coronary syndromes. 
3. Systemic hypertension. 
4. Heart failure with impaired LV systolic 
function. 
5. Congestive cardiomyopathy. 
6. Hypertrophic cardiomyopathy. 
7. Arrhythmias: sinus tachycardia, PVCs, 
supraventricular tachycardia, ventricular 
tachycardia, long QT syndrome. 
8. Aortic dissection. 
9. Tetralogy of Fallot. 
10. Mitral valve prolapse. 
11. Digitalis intoxication. 
1. Migraine prophylaxis. 
2. Essential tremors. 
3. Anxiety (situational). 
4. Thyrotoxicosis. 
5. Alcohol withdrawal. 
6. Glaucoma. 
 
Beta-adrenoceptor antagonists are a mainstay in the treatment of 
chronic, stable angina. While coronary blood flow (ie, oxygen supply) may be 
sufficient to meet myocardial oxygen requirements at rest in patients with fixed 
atherosclerotic lesions, the obstruction prevents blood flow from increasing 
during periods of increased oxygen demand. Under these conditions coronary 
blood flow is already at a maximal level in most patients, thus any increase in 
myocardial work can trigger an episode of acute angina. Precipitating factors 
include physical exertion, emotional stress or excitement, and temperature 
extremes. By decreasing heart rate, myocardial contractility, and afterload, b-
adrenoceptor antagonists reduce myocardial workload and oxygen consumption 
at rest as well as during periods of exertion or stress. Oral b-adrenoceptor  an-
tagonists are widely used in long-term maintenance therapy to prevent acute 
ischemic episodes. Prophylactic use of these agents reduces the frequency and 
severity of acute anginal attacks. Because of their slow onset of action, oral b-
adrenoceptor antagonists are not appropriate for terminating an acute attack of 
angina once it has begun; sublingual nitroglycerin is the agent most frequently 
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used under these conditions. Several b-adrenoceptor antagonists, including 
propranolol, metoprolol, and atenolol, have cardioprotective effects and have 
been shown to decrease mortality after myocardial infarction. 
In patients with variant (Prinzmetal’s) angina, the major underlying cause of an-
gina is vasospasmof one or more coronary arteries. Intense vasoconstriction decreases 
coronary blood flow, thereby reducingmyocardial oxygen supply. Coronary vasospasm 
can occur in arteries with little or no atherosclerotic plaque and is not associated with an 
increase in myocardial oxygen demand.  Indeed, variant angina may strike at any time 
of the day or night, including during periods of rest or sleep. In contrast to stable angina, 
variant angina is most often the result of an abrupt decrease in myocardial oxygen sup-
ply (ie, coronary blood flow) rather than an increase in myocardial oxygen demand. 
Unlike nitrates and calcium channel blockers, b-adrenoceptor antagonists do not directly 
dilate coronary arteries to increase coronary blood flow. 
Moreover, blockade of vascular b-adrenoceptors inhibits the vasodilator actions 
of endogenous catecholamines and may exacerbate a-adrenoceptor-mediated vasocon-
striction in coronary arteries. Thus, b-adrenoceptor antagonists may worsen coronary 
vasospasm and are not indicated for treatment of vasospastic angina. 
Beta-adrenoceptor antagonists may reduce the risk of progression to acute 
myocardial infarction in patients with unstable angina. The pathophysiology of this 
condition is often complex and may involve several underlying factors superimposed 
upon one another, including rupture of atherosclerotic plaques and thrombus forma-
tion, constriction of coronary arteries, and increased myocardial oxygen demand. In 
these patients, the beneficial effects of the b-adrenoceptor antagonists are likely due to 
a reduction in myocardial oxygen consumption. If coronary vasospasm is the major 
underlying problem, nitrates or calcium channel blockers would be more effective and 
b-adrenoceptor antagonists should be used with caution. 
Table 9. 
Contraindications of BABS 
 
Absolute Relative 
1. Cardiogenic shock. 
2. Hypotension (SBP< 85 mmHg). 
3. Acute pulmonary oedema. 
4. Signs of systemic hypoperfusion: mental deterioration, 
cold clammy skin, rising BUN. 
5. Congestive heart failure with pulmonary crepitations 
more than one half of the chest or significant volume over-
load (until adequate diuresis). 
6. Symptomatic bradycardia (heart rate < 50/m) or more 
than grade I AV block in absence of pacemaker. 
7. Patients receiving IV inotropes. 
8. Status asthmaticus or bronchospasm requiring inhaled beta-agonists
1. Bronchial 
asthma or 
COPD. 
2. Heart  
failure. 
3. Insulin 
dependent 
diabetes  
mellitus. 
4. Severe 
PVD. 
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In angina pectoris (chronic stable and unstable) 
 Start with a small dose and build the dose over days, monitor heart 
rate and blood pressure. 
 ll types of BABs appear to be equally effective in exertional angina 
but there is interindividual variability in responsiveness. 
 Evaluate anginal symptoms in 1 to 2 weeks. 
 Starting dose of atenolol is 25 mg once daily which can be increased 
as tolerated to a maximum of 200 mg once daily (assuming the renal function is 
normal) until the resting heart rate is 50 to 60 beats/min and does not exceed 
100 beats/min with ordinary activity. 
 Starting dose of metoprolol is 25 mg BID, which can be increased to 
200 mg BID as tolerated. 
 The efficacy of BABs in relieving angina is dose-dependent.  
It is important to be certain that adequate beta blockade has been at-
tained. BABs dose is titrated to achieve the following goals: 
1. Resting heart rate between 50 and 60 beat/min. Target heart rate for 
some patients with more severe angina can be less than 50 beats/min, as long as 
bradycardia is asymptomatic and heart block does not develop. 
2. Blunting of postural increase in heart rate. 
3. Blunting of peak heart rate and blood pressure during exercise, meas-
ured during exercise testing. 
4. Reduction in the frequency and severity of angina and in use of sub-
lingual nitroglycerin.  
The following are cardioprotective doses proved effective in preventing 
sudden death and total cardiac deaths in patients after MI. The beneficial effect 
of smaller doses is unknown: 
 Metoprolol 100-300 mg/d. 
 Propranolol (non smokers) 160-240 mg/d 
 Timolol 10-20 mg/d 
BABs are not effective in Prinzmetal (vasospastic angina) and should 
not be used in this condition. 
Avoid abrupt cessation of therapy when it is necessary to discontinue 
BABs. The dose should be reduced gradually over 2 to 3 weeks. 
Adverse effects of BAB 
1. Cardiac 
 Myocardial depression and precipitation of heart failure. 
 Profound bradycardia, sinus node dysfunction and AV conduction delay. 
 Hypotension. 
2. Peripheral vascular effects 
 Cold extremities. 
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 Absent pulses, cyanosis. 
 Raynaud's phenomenon. 
 Worsening of claudication. 
3. Central nervous system effects 
(more common with highly lipid soluble BABs such as propranolol and 
metoprolol) 
 Dreams, halluacinations, insomnia. 
 Depression. 
 Fatigue. 
 Impotence. 
4. Metabolic effects 
 Enhancement of insulin induced hypoglycemia. 
 Masking manifestations (tachycardia) of hypoglycemia. 
 Hyperlipidemia: increase in plasma triglycerides and decrease in 
HDL-cholesterol secondary to inhibition of lipoprotein lipase activity. 
5. Rebound phenomenon 
 Sudden discontinuation of BAB specially if it has been administered 
for a long time (> 3 weeks) can lead to profound elevation of blood pressure 
and tachycardia and may precipitate myocardial ischemia, or infarction. 
6. Ventilatory function 
 Bronchopasm and increase airway resistance in asthmaticsCalcium an-
tagonists. For the management of IHD, calcium channel blockers (verapamil, dilti-
azem, nifedipine, amlodipine) are generally considered in patients who have contrain-
dications to b-blockers (i.e, Prinzmetal angina and other contraindications discussed 
previously). This is because in some post-MI clinical trials, calcium channel blockers 
increased mortality in patients with left ventricular dysfunction. 
Calcium channel blockers. Calcium channel blocking agents (CCB) 
inhibit the entry of calcium into vascular smooth muscle cells and myocardial 
cells during the action potential. 
CCBs are a heterogenous group of drugs with widely variable effects on 
heart muscle, sinus node function, atrioventricular (AV) conduction, peripheral 
blood vessels and coronary circulation. 
Classification 
1. Dihydropyridines (DHP) 
Include: Nifedipine, Amlodipine, Nicardipine, Felodipine, Nisolidipine, 
Isradipine. 
2. Nondihydropyridines 
Include: 
 Phenylalkylamines: verapamil. 
 Benzothiazepines: diltiazem 
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Mechanism of anti-ischemic action 
1. Increase coronary blood flow 
 Decrease coronary vascular resistance- coronary vasodilatation. 
 Increase collateral blood flow. 
 Decrease coronary spasm. 
The most effective in this action is nifedipine 
2. Decrease myocardial oxygen demand 
 Bradycardia: most effective is verapamil. Nifedipine produces reflex 
tachycardia. 
 Reduction in blood pressure: all members lower blood pressure, the 
most effective is nifedipine. 
 Decrease in myocardial contractility. Most potent is verapamil. 
3. Other actions 
Decreased platelet aggregation. 
DHP calcium antagonists are powerful vasodilators, they possess negli-
gible negative inotropic and electrophysiologic effects. They are ineffective as 
antiarrhythmic agents.  
Verapamil is a moderately potent vasodilator but has a marked negative 
inotropic effect. It produces mild depression of sinus node function and of AV 
conduction. It is effective in the termination of AV nodal reenterant tachycardia. 
Stable angina pectoris 
CCBs are used as second line drugs and as effective alternatives or ad-
ditional drugs in patients who remain symptomatic despite therapy with beta 
blockers and nitrates. They can be used as first-line antianginal drugs in pa-
tients with contraindications to beta blockers. 
Coronary vasospasm and prinzmetal angina 
CCBs are drugs of first choice in this syndrome because of their ability 
to block spontaneous and drug induced spasm. 
Vasospastic angina is characterized by angina usually at rest specially in 
the morning with ST elevation and usually with preserved exercise capacity. 
Most patients have some degree of underlying epicardial CAD. 
Coronary spasm and/or thrombosis play a major role in the pathogenesis 
of ischemia in most patients with angina at rest, regardless of the coronary 
anatomy. 
Drug interaction with verapamil 
 Beta-blockers 
Verapamil should not be given as IV bolus to patients receiving B-
blockers. It is preferable to give oral preparation. 
 Digoxin 
Verapamil should never be given to digitalized patient when digitalis toxicity 
is suspected. Serum digoxin levels may be increased by 50 -70 % by verapamil. 
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 Amiodarone 
Verapamil is avoided in patients taking amiodarone because of depres-
sion of SA and AV nodes. 
 Oral Anticoagulants 
Verapamil increases the effects of oral anticoagulants. 
 Quinidine 
Plasma levels of quinidine may increase during the administration of 
verapamil. Marked hypotension may develop with IV verapamil. 
 Disopyramide 
Added negative inotropic effect can result in heart failure. 
Contraindications 
Contraindications for non-DHP (verapamil, diltiazem) CCBS 
1. Severe impairment of LV systolic function, CHF, or pulmonary oedema. 
2. Sinus node dysfunction and AV block (second and third degree). 
3. WPW with AF. 
Other contraindications to CCBs 
1. Cardiogenic shock. 
2. Profound hypotension (SBP < 90 mmHg). 
3. Pregnancy and lactation. 
4. Significant aortic stenosis. 
5. Rapid-release short acting nifedipine must be avoided in the absence 
of adequate concurrent beta-blockade in acute coronary syndromes. 
Adverse effects 
Four percent of patients discontinue CCBs because of side effects. 
1. Hypotension and dizziness. 
2. Oedema of ankles and lower limbs (more common with amlodipine). 
3. Headache: more with DHPs. 
4. Flushing and burning: more with DHPs. 
5. Constipation common with verapamil. 
Combination therapy. Combination therapy with drugs from different 
pharmacologic classes is often used in the long-term management of patients 
with angina. This strategy takes advantage of the diverse mechanisms of action 
of drugs from each category and offers several potential benefits. When used 
concurrently, b-adrenoceptor antagonists can inhibit the baroreceptor-mediated 
reflex tachycardia and positive inotropic effects that may sometimes occur with 
organic nitrates. Alternatively, organic nitrates increase venous capacitance and 
can thereby offset b-adrenoceptor antagonist-mediated increases in left ven-
tricular end-diastolic volume. Moreover, organic nitrates are coronary vasodila-
tors and, as such, may prevent the increase in coronary vasomotor tone that 
may potentially result from blockade of vascular b-adrenoceptors. 
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Dihydropyridine calcium channel blockers are also potent coronary 
vasodilators and provide similar advantages with regard to coronary vascular 
resistance in patients treated simultaneously with b-adrenoceptor antagonists. 
As with nitrates, dihydropyridines may also cause reflex tachycardia that can be 
alleviated by b-adrenoceptor antagonists. Concurrent use of b-adrenoceptor 
antagonists with the non-dihydropyridine calcium channel blockers, verapamil 
and diltiazem, is much more limited due to the potential for severe cardiac 
depression and must be used with great caution.  
In the long-term management of ischemic heart disease, b-adrenoceptor 
antagonists, with their antianginal effects, may also be combined with vasculo-
protective drugs such as anti-platelet agents (aspirin, clopidogrel), angiotensin-
converting enzyme inhibitors, and HMG-CoA reductase inhibitors to reduce the 
risk of ischemic vascular events. 
Metabolic antianginal drugs 
Drugs 
 Perhexiline 
 Trimetazidine 
 Ranolazine 
 Etomoxir 
 Nicorandil 
 
This group exerts its anti-ischemic effect through metabolic action and 
have little or no effect on coronary hemodynamics. 
They do not affect blood pressure, pulse rate or LV systolic function. 
They have considerate potential as adjunctive therapy for angina, par-
ticularly in patients refractory to standard therapy. They may be a primary 
therapeutic option in certain circumstances. 
These agents (trimetazidine, ranolazine, and perhexiline) have docu-
mented anti-ischemic effects. They are, in theory, useful in patients with angina 
secondary to hypertrophic cardiomyopathy, aortic stenosis, and cardiac syn-
drome X (microvascular disease) due to their anti-ischemic effects in the ab-
sence of vasodilatation. 
They may be of potential benefit in heart failure as some can improve 
myocardial function. 
Myocardial metabolism 
Sixty to ninety percent of the energy generated by the normal adult 
heart is from free fatty acids (long-chain free fatty acid, LCFA). LCFA entry 
into the mitochondria is facilitated by the enzyme carnitine-palmityl-transferase 
(CPT). 
Carbohydrate metabolism contributes only to about 10-40% of energy 
generated by the healthy human adult heart. 
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Fatty acids require approximately 10-15% more oxygen to generate an 
equivalent amount of ATP when compared to glucose. 
Suppression of FFA uptake and/or oxidation stimulates an increase in 
myocardial glucose utilization. 
Perhexiline 
It acts by shifting myocardial substrate utilization from fatty acids to 
carbohydrates through inhibition of CPT, resulting in increased glucose and 
lactate utilization. 
Perhexiline can cause hepatic toxicity and peripheral neuropathy, but this risk 
can be reduced by maintaining a low plasma concentrate between 150 to 600 ng/mL. 
The mechanism for toxicity appears to be due to phospholipids accumu-
lation, which is a direct consequence of CPT inhibition. 
The drug improves angina frequency and exercise capacity. 
It is used as adjunctive treatment for refractory angina in patients not 
suitable for, or awaiting, coronary intervention. It is given as a short-term ther-
apy (less than 3 months). 
Serum level monitoring is necessary when perhexiline is administered. 
Dose: 100 mg twice daily with subsequent plasma guided dose titration. 
Trimetazidine 
It exerts no significant negative inotropic or vasodilator properties. 
It reduces the rate of FFA oxidation (free fatty acid), with a concomitant 
increase in glucose oxidation rates during ischemia, but the exact molecular 
mechanism of action is unclear. The metabolic effect of 
trimetazidine is mediated by inhibition of mitochondrial long-chain 3-
ketoacyl Co A thiolase, a fundamental enzyme that operates in the FFA beta-
oxidative chain. As a result, myocardial glucose oxidation is increased and 
substrate utilization is shifted from fatty acid to carbohydrate metabolism. 
It has a favorable side-effect profile. 
In clinical trials (meta-analysis) trimetazidine demonstrated a significant 
reduction in anginal frequency in patients with stable angina, but only a non-
significant trend towards prolongation of the duration of treadmill exercise. 
It improves resting ventricular function in patients with CAD and vari-
ous degrees of contractile impairment. 
It has no short or long term mortality benefit when infused intrave-
nously immediately post-MI for 48 hours. 
Though the clinical efficacy of trimetazidine has been demonstrated, yet, 
there is uncertainty regarding its role, particularly its safety profile at higher doses in 
management of CAD. It remains a potential treatment for the future 
Dose: two forms 
- Short acting: 20 mg three times a day. 
 Slow release (MR): 35 mg twice a day. 
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Ranolazine 
It stimulates glucose oxidation and act as a partial fatty-acid-oxidation 
inhibitor. It inhibits fatty-acid oxidation during the periods of elevated plasma 
FFA levels associated with myocardial ischemia. 
It has a significant antianginal effects both as monotherapy and in com-
bination with other antianginal agents. 
Two studies using high doses of ranolazine (up to 1500 mg twice daily) 
in patients with chronic stable angina either as monotherapy (MARISA study) 
or as background antianginal therapy (CARISA study) showed that ranolazine 
significantly increased duration of exercise, time to angina and fewer anginal 
episodes compared to placebo. There was minor prolongation of QT interval. 
Long term safety, particularly with relation to QT prolongation is not 
known. 
Etomoxir 
It was initially introduced as a potential antidiabetic agent on the basis 
of its hypoglycemic effects. 
It is potent CPT inhibitor (Carnitine palmitoyl-transferase enzyme inhibition)  
It is an experimental drug. 
In experimental animals, it reduces oxygen consumption during 
ischemic recovery and prevented epression of myocardial function. 
Etomoxir administered 80 mg/day to patient with heart failure, im-
proved LV ejection fraction and clinical status. 
Nicorandil 
A vasodilator that opens ATP-sensitive potassium channels in blood 
vessels and heart muscle. 
Possibly its action is through enhancing ischemic preconditioning, a 
process whereby one episode of ischemia makes the heart more tolerant to 
subsequent episodes. 
It may have also anti-adrenergic actions by inhibition of norepinephrine 
release. 
It resulted in a 17% reduction in the relative risk of nonfatal MI or un-
planned hospitalization for angina (IONA trial, 2001). 
Nicorandil can be a useful adjuvant to the treatment of patients with 
chronic angina 
ACE inhibitors. In patients who have chronic stable angina and left 
ventricular dysfunction, ACE inhibitors should be used to reduce the progres-
sion of left ventricular dysfunction and prevent future cardiovascular events 
(more discussion to follow in heart failure lecture). 
Recent clinical trials have demonstrated that the use of certain ACE inhibi-
tors (ie, Ramipril) in patients with hypertension, diabetes, or IHD, even with normal 
left ventricular dysfunction, can reduce future cardiovascular events. The issue of 
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tissue versus non-tissue ACE inhibitors is discussed here, but the issue is controver-
sial. Therefore, as long as patient blood pressure can tolerate, ACE inhibitors should 
be added. If patients cannot tolerate ACE inhibitors due to cough, an angiotensin 
receptor blocker (ARB) can be used instead. 
Antiplatelet agents. Examples of antiplatelet agents are aspirin, clopi-
dogrel, and glycoprotein IIb/IIIa receptor antagonists. Aspirin and clopidogrel 
can be used across the spectrum of IHD. Glycoprotein IIb/IIIa receptor antago-
nists are used in patients with ACS only, as part of their in-hospital regimen. 
Aspirin. There is strong evidence that the use of aspirin in IHD can re-
duce future cardiovascular events. Therefore, unless absolutely contraindicated, 
patients across the spectrum of IHD should receive aspirin, 81-325 mg orally, 
once a day, indefinitely. 
Clopidogrel. Clopidogrel has been demonstrated to reduce cardiovascular 
events in IHD, and may be slightly more effective than aspirin (based on one study). 
Clopidogrel is to be used in patients who cannot tolerate aspirin for primary and secon-
dary prevention of MI. In patients who have coronary stent placement, clopidogrel 
should to be used in combination with aspirin for 12 months after stent placement to 
prevent stent thrombosis. There are also clinical data demonstrating that the early initia-
tion of aspirin and clopidogrel combined therapy in patients with unstable angina or 
NSTEMI is better than aspirin alone in reducing recurrent cardiovascular events. Data 
on combination use of aspirin and clopidogrel beyond 12 months is not available. 
Glycoprotein IIB/IIIA receptor antagonists. Glycoprotein IIB/IIIA re-
ceptor antagonists are currently only available in intravenous forms and there-
fore only used for managing ACS in hospitals. They are used during precutane-
ous coronary intervention to prevent acute platelet aggregation and thrombosis. 
The 2 small molecules glycoprotein IIb/IIIa inhibitors (tirofiban and eptifi-
batide) can also be used for medical stabilization of patients.  
Specific treatment endpoints. Specific endpoints are to ensure blood pressure 
,140/90 mm Hg (according to JNC VII guidelines, blood pressure goal is ,140/90 mm 
Hg and in patients with diabetes or chronic kidney disease, it is 130/80 mm Hg), a rest-
ing heart rate of 50 or 60 beats per minutes, and to improve exercise tolerance. 
Monitoring parameters and monitoring frequency. Monitoring parame-
ters include blood pressure, heart rate, and episodes of symptoms and side ef-
fects of individual pharmacologic agents. Since this is a stable angina case, the 
patient can be encouraged to obtain a home blood pressure monitoring device 
to check his own blood pressure and heart rate several times a week and during symp-
toms. The patient should have regular follow-up visits with his physicians. The patient 
should report any increase in symptoms or intolerable side effects to drugs immediately. 
Patient counseling. In general, patients with any form of IHD should receive education 
regarding symptoms of ACS and seeking prompt medical assistance as appropriate. Also, 
patients should be educated to modify their lifestyles and properly manage their risk factors. 
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At this point, the guidelines for treatment of chronic stable angina 
are summarized: 
 Every patient should receive aspirin, 81-325 mg daily, indefinitely (if 
allergic to aspirin, may use clopidogrel, 75 mg daily). 
 Patients who have coronary stents should receive aspirin and clopido-
grel together for 12 months, then back to aspirin alone (dose of aspirin is 325 
mg for the first month, then 81 mg thereafter). 
 All patients should have sublingual nitroglycerin for relief of chest 
pain as needed. 
 Add b-blockers, then titrate until resting heart rate reaches approxi-
mately 50 to 60 beat per minute. 
 If use of b-blockers are contraindicated or if patient has Prinzmetal an-
gina, use calcium channel blockers. 
 Add long-acting nitrates if angina is frequent (make sure a 6- to 12-
hour nitrate-free interval is incorporated into the regimen). 
 Never use nitrates alone without b-blockers or calcium channel block-
ers as an antianginal. 
 A combination of b-blockers, and calcium channel blockers (and ni-
trates) may be used for severe disease (titrate to the most optimal dose based on 
heart rate, blood pressure, and symptoms). 
Use lipid lowering drugs: 
 All patients with angina pectoris should have a lipid profile done. Diet 
modifications and use of lipid lowering drugs are indicated for lowering total 
cholesterol to <200 mg/dl and LDL cholesterol to <100 mg/dl. 
 If baseline LDL cholesterol is > 100 mg/dl, LDL lowering drug ther-
apy should be initiated in addition to therapeutic lifestyle changes. When LDL 
lowering therapy is used in high-risk or moderately high-risk persons, intensity 
of therapy should be sufficient to achieve a 30-40% reduction in LDL choles-
terol levels. Reduction of LDL cholesterol to <70 mg/dl with high-dose statin 
therapy can be considered for CV risk reduction. 
 Drug combinations (eg. statin-ezetimibe combination) are beneficial 
for patients on lipid lowering therapy who are unable to achieve LDL-C < 100 
mg/dL or LDL-C < 70 mg/dL 
 If triglycerides are 200-499 mg/dl, non-HDL cholesterol should be 
maintained to <130 mg/dl. Fibrate and niacin therapy can be useful options to 
reduce non-HDL cholesterol. 
 If triglycerides are > 500 mg/dl, fibrates or niacin should be used to 
lower the triglyceride in order to reduce the risk of pancreatitis; these should be 
initiated before LDL cholesterol lowering therapy. 
 If HDL cholesterol is < 40 mg/dl, consider niacin or fibrate therapy  
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Table 10  
Drugs: dosage guidelines 
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Table 11.  
Drugs: Side-effects & contraindications 
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Myocardial revascularization 
Percutaneous coronary intervention (PCI) is recommended in follow-
ing group of patients: 
 Two- or three-vessel disease with significant proximal LAD CAD, 
who have anatomy suitable for catheter-based therapy & normal LV function & 
who have untreated diabetes. 
 Significant left main coronary disease who are not candidate for 
CABG. 
 One- or two-vessel CAD without significant proximal LAD CAD but with a 
large area of viable myocardium and high-risk criteria on non-invasive testing. 
 One- or two-vessel CAD without significant proximal LAD CAD who 
have survived sudden cardiac death or sustained ventricular tachycardia. 
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Percutaneous transluminal coronary angioplasty (PTCA) was origi-
nally introduced as a balloon angioplasty, a procedure that involved using a 
catheter-borne balloon that was inflated at the site of coronary stenosis. The 
scope of this procedure has widened to include the use of stents, atherectomy 
and laser therapy.  
The following are the important indications for angioplasty: 
 Stable angina in patients with suitable coronary anatomy who are un-
controlled on or intolerant of medical treatment. 
 Two- or three-vessel disease with significant proximal left anterior de-
scending artery disease, in patients who have normal anatomy suitable for 
catheter-based therapy, normal left ventricular function, and who do not have 
treated diabetes. 
 Unstable angina not responding to medical treatment. 
 Unstable angina or AMI followed by a positive exercise test. 
 AMI complicated by cardiogenic shock. 
 AMI where thrombolytic drugs are contraindicated. 
 One- or two-vessel disease without a significant disease of proximal 
left anterior descending artery but with a large area of viable myocardium and 
high-risk criteria on noninvasive testing. 
Disadvantages. Angioplasty has similar mortality to coronary artery 
bypass grafting (CABG), with 1% mortality for the treatment of single-vessel 
disease, and 2% when more than one vessel is dilated. About 3% of people 
need an emergency heart bypass due to damage to the coronary artery during 
angioplasty. Almost one third of patients experience restenosis within 3 months 
and again require angioplasty. Of those who have angioplasty on more than one 
vessel, almost half have restenosis of one or more vessels. Almost one fifth of 
patients who have angioplasty require heart bypass within 3 years. 
 
STENTS 
 
A coronary stent (scaffold) is an artificial support device in the coronary 
artery to keep the vessel open. It was developed to overcome the two primary 
limitations of balloon angioplasty: sudden closure of the coronary artery and 
late restenosis. Stents prevent narrowing of the coronary artery by providing a 
scaffolding lattice to tack back the inner surface of the coronary artery. It pre-
vents late restenosis by mechanically enforced remodeling and resetting of the 
vessel size of the stented segment. In 20% to 40%, restenosis gradually occurs. 
There are several different coronary stents available, and the scaffolding 
lattice of each stent differs markedly in configuration. Coronary artery stenting 
is currently applicable only to relatively large arteries (>3mm diameter). The 
stents can be categorized into the mesh stents, characterized by strong and ex-
tensive scaffolding of the vessel wall (Wallstent, Palmaz-Schatz, and AVE 
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Micro) and the coil stents, characterized by a low metallic surface area and 
predominantly transverse strut orientation (Gianturco-Roubin, Wiktor, Mul-
tilink, and Cordis). Drug-eluting stents (DESs) are now used and have been 
shown to dramatically reduce the risk of restenosis compared with bare metal 
stents. In the Sirolimus-Eluting Coronary Stent (SIRUS) Trial, 1058 patients 
undergoing elective coronary stent implantation were randomized to a bare 
stent or the sirolimus DES. The patients were followed-up for a year. The si-
rolimus stent reduced the restenosis rate by 75%, from 36.3% to 8.9%, and 
reduced the rate of repeat revascularization from 28.4% to 13%. No significant 
advantage was found with regard to mortality and MI. 
Coronary stenting usually follows balloon angioplasty, which re-
quires inserting a guide catheter at the ostium of the coronary artery 
through the femoral artery. The guide wire is then manipulated beyond the 
lesion, after which the balloon catheter is inserted over it. When this cathe-
ter is positioned at the site of blockage, it is slowly inflated to widen the 
coronary artery and is then removed. 
The stent-mounted catheter is then threaded into the artery. When this is 
correctly positioned in the coronary artery, the balloon is inflated, expanding 
the stent against the wall of coronary artery. The balloon catheter, guide wire, 
and guide catheter are then removed, leaving the stent. A cardiac angiography 
follows to ensure that the stent is keeping the artery open. Aspirin is taken for 
few days before the procedure in the dose of 300mg a day. There is a small risk 
that the stented artery may close. Thrombosis, bleeding, and artery damage are 
rare complications. 
Coronary artery bypass grafting (CABG) New minimally invasive op-
erative procedures that do not require cardiopulmonary bypass may extend its use 
to patients who are at greater risk of surgery. Arterial grafts can be used not only 
from the internal mammary artery but also from the right gastroepiploic artery, 
inferior epigastric artery, and radial artery. Arterial grafts have many advantages 
over saphenous vein grafts. They have a reduced propensity to develop atheroscle-
rosis. Reviews of patients treated with internal mammary artery grafting of left 
anterior descending artery have shown improved long-term survival, a lower long-
term incidence of angina, and higher graft patency rates. Fourteen percent of coro-
nary bypass operations are now reoperations. Repeat grafting is associated with 
higher operative risk (3%). Symptom-free patients, without complication, can be 
expected to return to work in 4 to 8 weeks. 
The important indications for CABG are as follows: 
 Patients with significant left main artery disease. One- or two-vessel disease 
without significant proximal left anterior. 
 descending artery disease but with a large area of viable myocardium 
and high-risk criteria on noninvasive testing. 
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 Patients with three-vessel disease; the surgical benefit is better with 
left ventricular dysfunction (ejection <50%). 
 Patients with two-vessel disease with significant proximal left anterior 
descending artery disease and left ventricular dysfunction (ejection <50%). 
 Patients with one- or two-vessel artery disease without proximal left 
anterior descending artery disease who survived sudden cardiac death or sus-
tained ventricular tachycardia. 
 Patients who have not been successfully treated by medical therapy. 
Some patients are suitable for either procedure (CABG or PCTA). 
Overall there is no evidence of a major difference between the two over 
3 to 5 years in the risk of death or heart attack. Occasionally, it is difficult to 
dilate all stenosed segments of the coronary artery at a single attempt of angio-
plasty, and restenosis occurs within 6 months in about one third of patients. 
Therefore, patients initially treated with angioplasty needed more repeat proce-
dures to restore blood circulation (30–50%) than did bypass patients (5–10%). 
Newer revascular techniques and their advantages: 
Coronary atherectomy devices 
Since PTCA does not remove the plaque but acts by splitting and shift-
ing the plaque and stretching the coronary artery, this led to the development of 
new devices that remove the plaque and also cause fewer traumas to the deeper 
components of the arterial wall. 
Atherectomy devices include directional, rotational atherectomy, trans-
luminal extraction, and excimer laser angioplasty. The directional coronary 
atherectomy is a nonballoon interventional device. It is a cutting device, as it 
cuts the plaque and leaves smooth lumen. It is a suitable procedure when le-
sions are ostial, eccentric, or present at bifurcations. Its contraindications in-
clude small vessel size, calcified lesions, lesion angulation, and proximal tortu-
osity of the vessel. 
Rotational atherectomy ablates plaque material. Percutaneous rotational 
atherectomy uses a high-speed metal burr coated with diamond clips to abrade 
and destroy plaques into fine microparticles. 
This technique is suitable for harder calcified, fibrotic lesions.  
It is contraindicated in patients with left ventricular dysfunction and in 
those with visible thrombus. 
Transluminal extraction atherectomy (TEC) increases luminal 
size by cutting material and aspirating it. The system comprises a conical 
cutting head with two stainless steel blades bound to the distal end of a 
hollow flexible torque tube. A suction bottle, which collects the excised 
lesions, and a battery-powered motor drive unit are attached to the proxi-
mal end of the tube. The is useful in lesions in which thrombus or debris 
has to be removed from the artery. 
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Coronary laser angioplasty 
Coronary laser angioplasty involves using excimer laser systems. It is a 
pulsed laser, that is, the energy is released in short bursts of ultraviolet light 
separated by relatively long periods of silence, during which laser emission is 
switched off. This procedure is indicated in saphenous vein graft lesions, long 
lesions, osteal lesions, and total occlusions. Its contraindications include bifur-
cation lesions, highly eccentric lesions, severe lesion, angulation, vessel tortu-
osity, and prior dissection. 
Transmyocardial laser revascularization (TMR) 
Transmyocardial laser revascularization with the aid of a laser makes 
small channels into the myocardium, which lead to improved exercise toler-
ance. The procedure is performed in the operating theater (with carbon dioxide 
or holmium: yttrium-aluminumgarnet [YAG] laser) or by a percutaneous ap-
proach. Although this technique gives symptomatic improvement in chronic 
stable angina, no definite benefits have been shown in terms of increasing myo-
cardium perfusion. 
Spinal cord stimulation 
This method involves accurate placement of the stimulating electrode in 
the dorsal epidural space, usually at the C7-T1 level. This method is proposed 
for patients with chronic stable angina refractory to medical, catheter interven-
tion, and surgical therapy. 
Summary  
 Stable angina pectoris is a common and disabling disorder 
 With proper management, the symptoms can usually be controlled and 
the prognosis substantially improved 
 As a minimum, each patient should have a carefully taken history and 
physical examination, and assessment of risk factors and a resting electrocar-
diogram 
 Short-acting nitrates should be offered either sublingually or via spray 
formulation to all angina patients 
 Patients should be prescribed lipid lowering drugs if they have an ab-
normal lipid profile (LDL-cholesterol > 100 mg/dl, triglyceride > 200 mg/dl, 
HDL-cholesterol < 40 mg/dl) 
 Aspirin 75-162 mg/day should be administered indefinitely to all an-
gina patients, unless contraindicated 
 RAAS blockers (ACE inhibitors & ARBs when ACE inhibitors is in-
tolerant) should be used indefinitely, unless contraindicated, in all patients with 
left ventricular ejection fraction < 40%.  
If there are no other contraindications, a selective beta-blocker is the drug of 
choice for providing symptom relief. Other effective alternatives include long-acting 
nitrates, calcium channel blockers, potassium channel openers and cytoprotective drugs. 
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 Beta blockers should be used indefinitely in all patients who had MI, 
acute coronary syndrome, or left ventricular dysfunction with/without heart 
failure symptoms unless contraindicated 
 Combination is recommended when a single drug is ineffective. Third 
drug can be added after proper evaluation & when only if optimal 2 drugs 
regimens is insufficient  
 Revascularization (CABG or PCI) is indicated in angina patients 
who are not controlled by medical therapy & when there are anatomically 
suitable lesions.  
 Revascularization relives the symptoms of angina & reduces the risk 
of mortality particularly in recommended sub-groups of patients. 
 
10. TESTS AND ASSIGNMENTS FOR SELF-ASSESSMENT  
FINAL LEVEL OF KNOWLEDGES 
 
1. Which of the following best describes variant or Prinzmetal’s angina?  
А. Angina at rest, often in early morning, associated with sinus 
     tachycardia (ST) elevation.  
В. Angina at rest, often in early morning, associated with ST depression.  
С. Angina with effort, often in early morning, associated with ST elevation.  
D. Angina with effort, often in early morning, associated with ST depression. 
 
2. Which of the following mediators are associated with acute coronary 
syndromes?  
А. Adenyl cyclase, growth hormone, and parathyroid hormone.  
В. Insulin-like peptides, thyroxin, and melatonin. 
С. Pancreatic growth factor, serotonin, and adenosine monophosphate.  
D. Thromboxane A2, serotonin, and adenosine diphosphate.  
 
3. Which of the following contributes to the beneficial effect of nitro-
glycerin?  
А. Decrease of ventricular compliance.  
В. Dilation of systemic veins.  
С. Increase of left ventricular preload.  
D. Increase of left ventricular afterload.  
 
4. How do slow calcium-channel blockers produce relaxation of vascu-
lar smooth muscle?  
А. Fragmenting thick filaments.  
В. Making no net change of influx of calcium.  
С. Reducing influx of calcium to the cell.  
D. Reducing influx of calcium to the lysosome organelle of the mito-
chondrion. 
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5. ß-blockers (ß-adrenergic agents) are used in the treatment of angina 
because:  
А. They decrease variables such as heart rate and myocardial contractility.  
В. They increase afterload and preload.  
С. They increase sinus node automaticity.  
D. They increase sympathetic tone to the myocyte. 
 
ANSWERS 
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